Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modified Long-Course Radiotherapy (Reduced vs. Conventional CTV), Sequential Chemotherapy and PD-1 Inhibitor in Locally Advanced, MSS, Mid-Low Rectal Cancer: An Open-Label, Two-Arm, Randomized, Prospective Phase II Clinical Trial (MODIFI-RC-I)

NCT06923345 is registered in ClinicalTrials.gov with Sixth Affiliated Hospital, Sun Yat-sen University as lead sponsor.

NCT NCT06923345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06923345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modified Long-Course Radiotherapy (Reduced vs. Conventional CTV), Sequential Chemotherapy and PD-1 Inhibitor in Locally Advanced, MSS, Mid-Low Rectal Cancer: An Open-Label, Two-Arm, Randomized, Prospective Phase II Clinical Trial (MODIFI-RC-I)
Lead sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Phase
Phase 2
Overall status
Recruiting
Start date
March 31, 2025
Completion date
December 31, 2028
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune checkpoint therapy, neoadjuvant therapies, radiotherapy, rectal cancer